{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:06:03Z","timestamp":1782187563226,"version":"3.54.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>ATX-101 is indicated for submental fat treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>Evaluate ATX-101 versus placebo for reducing submental fat.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Adults with unwanted submental fat across 6 global sites were randomized to ATX-101 (0.5%, 1.0%, or 2.0%) or placebo for \u22644 treatments every 28 days. Outcomes included safety (adverse events and pain visual analog scale) throughout the study and efficacy (submental fat rating, patient satisfaction, and submental fat improvements) at Week 16.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Eighty-four of 85 enrolled patients received \u22651 ATX-101 treatment (0.5% [<jats:italic toggle=\"yes\">n<\/jats:italic> = 20], 1.0% [<jats:italic toggle=\"yes\">n<\/jats:italic> = 20], 2.0% [<jats:italic toggle=\"yes\">n<\/jats:italic> = 22] or placebo [<jats:italic toggle=\"yes\">n<\/jats:italic> = 22]). Most patients (<jats:italic toggle=\"yes\">n<\/jats:italic> = 82) experienced adverse events, which were mostly mild\/moderate, seemed to be dose-related, and led to no study discontinuations. The mean pain scores were highest in the ATX-101 1.0% and 2.0% groups. Week-16 change from baseline in the submental fat rating scale was significantly greater for ATX-101 0.5% and 1.0% versus placebo (<jats:italic toggle=\"yes\">p<\/jats:italic> \u2264 .05). At Week 16, 71%, 74%, 53%, and 40% of patients in the ATX-101 0.5%, 1.0%, 2.0%, and placebo groups, respectively, achieved a \u22651-grade reduction in submental fat from baseline. Satisfaction with appearance and patient-assessed global improvement ratings increased in all ATX-101 treatment groups versus placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>All ATX-101 concentrations were safe and efficacious for moderate\/severe submental fat reduction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003092","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T15:27:43Z","timestamp":1623425263000},"page":"1065-1070","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Randomized, Placebo-Controlled Phase 1\/2 Study to Determine the Appropriate ATX-101 Concentration for Reduction of Submental Fat"],"prefix":"10.1097","volume":"47","author":[{"given":"Greg J.","family":"Goodman","sequence":"first","affiliation":[{"name":"Department of General Practice, Monash University, Clayton, VIC, Australia;"},{"name":"University College of London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda J.","family":"Spelman","sequence":"additional","affiliation":[{"name":"Private Practice, Veracity Clinical Research, Woolloongabba, Brisbane, QLD, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lowe","sequence":"additional","affiliation":[{"name":"Private Practice, Cranley Clinic, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beta","family":"Bowen","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"R1-20250731","first-page":"1","article-title":"Sodium deoxycholate for submental contouring","volume":"21","author":"Humphrey","year":"2016","journal-title":"Skin Ther Lett"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coms.2008.10.008","article-title":"Complications of neck liposuction and submentoplasty","volume":"21","author":"Koehler","year":"2009","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/01676830601034532","article-title":"Aesthetic surgery of the aging neck: options and techniques","volume":"25","author":"Patel","year":"2006","journal-title":"Orbit"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjd.12695","article-title":"Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study","volume":"170","author":"Rzany","year":"2014","journal-title":"Br J Dermatol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/lsm.20807","article-title":"Injectable treatments for adipose tissue: terminology, mechanism, and tissue interaction","volume":"41","author":"Rotunda","year":"2009","journal-title":"Lasers Surg Med"},{"key":"R9-20250731","first-page":"178","article-title":"Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects","volume":"33","author":"Yagima Odo","year":"2007","journal-title":"Dermatol Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/jdv.12377","article-title":"Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study","volume":"28","author":"Ascher","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/DSS.0000000000000578","article-title":"REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction","volume":"42","author":"Jones","year":"2016","journal-title":"Dermatol Surg"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2016.04.028","article-title":"ATX-101 for reduction of submental fat: a phase III randomized controlled trial","volume":"75","author":"Humphrey","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00266-014-0364-9","article-title":"Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat","volume":"38","author":"McDiarmid","year":"2014","journal-title":"Aesthet Plast Surg"},{"key":"R14-20250731","first-page":"870","article-title":"ATX-101 (deoxycholic acid injection) for reduction of submental fat: results from a 12-month open-label study","volume":"18","author":"Beer","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R15-20250731","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjab100","article-title":"Improvements in submental contour achieved with ATX-101 are maintained for up to 3 years: efficacy and safety follow-up of the phase 3 REFINE trials","author":"Humphrey","year":"2021","journal-title":"Aesthet Surg J"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/asj\/sjy008","article-title":"Efficacy and safety of ATX-101 by treatment session: pooled analysis of data from the phase 3 REFINE trials","volume":"38","author":"Dayan","year":"2018","journal-title":"Aesthet Surg J"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/00006534-198012000-00003","article-title":"Visual criteria for success in restoring the youthful neck","volume":"66","author":"Ellenbogen","year":"1980","journal-title":"Plast Reconstr Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:13:42Z","timestamp":1754000022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003092","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]}}}